ECM
STRO icon

Endurant Capital Management’s Sutro Biopharma STRO Stock Holding History

Endurant Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,190
Closed -$2.28M – 64
2022
Q4 		$2.28M Buy
28,190
+1,522
+6% +$106K 0.92% 23
2022
Q3 		$1.48M Sell
26,668
-9,079
-25% -$537K 0.48% 36
2022
Q2 		$1.86M Buy
35,747
+6,096
+21% +$341K 0.65% 35
2022
Q1 		$2.44M Buy
29,651
+18,471
+165% +$1.76M 0.64% 34
2021
Q4 		$1.66M Buy
+11,180
New +$2M 0.4% 47
2021
Q1 		– Sell
-17,205
Closed -$3.73M – 74
2020
Q4 		$3.73M Sell
17,205
-29,012
-63% -$4.8M 1.35% 28
2020
Q3 		$4.64M Buy
46,217
+30,616
+196% +$2.89M 1.37% 23
2020
Q2 		$1.21M Buy
+15,601
New +$1.5M 0.07% 47
2020
Q1 		– Sell
-3,267
Closed -$359K – 67
2019
Q4 		$359K Buy
+3,267
New +$337K 0.11% 48

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Endurant Capital Management's STRO Position: Q1 2023 in Review

Endurant Capital Management sold out of Sutro Biopharma (STRO) in Q1 2023, closing a stake of 28,190 shares — an estimated $2.28M sold.

Endurant Capital Management first reported a position in STRO in Q4 2019 and held it in 9 quarters. The position peaked at $4.64M in Q3 2020. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2023.

  • Endurant Capital Management reported no remaining Sutro Biopharma position as of Q1 2023 after selling out during the quarter.
  • Endurant Capital Management sold 28,190 Sutro Biopharma shares in Q1 2023, an estimated $2.28M.
  • Endurant Capital Management first reported a position in Sutro Biopharma in Q4 2019 and held it in 9 quarters.
  • Endurant Capital Management's Sutro Biopharma position peaked at $4.64M in Q3 2020.
  • 115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2023.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.